Oxylaxon

Active Ingredient:: Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate
Origin:: EU

Oxylaxon (Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone Hydrochloride, the active ingredient in Oxylaxon, is an opioid analgesic presented as a strength/form for oral use. It treats moderate to severe pain in adult patients when other analgesics are insufficient. GNH India supplies Oxylaxon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Oxylaxon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

G.L. Pharma Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxylaxon combines an opioid agonist with an antagonist to provide analgesia while reducing misuse potential.

Moderate to severe acute pain: alleviates pain intensity in postoperative or injury‑related settings.
Chronic cancer‑related pain: maintains long‑term pain control for oncology patients.
Severe chronic non‑cancer pain: offers sustained relief when other opioids are inadequate.

How It Works

Oxylaxon delivers oxy‑c‑d‑hydrochloride, a μ‑opioid receptor agonist, together with naloxone hydrochloride dihydrate, a peripheral opioid antagonist. The agonist activates central μ‑receptors to diminish pain signaling, while naloxone remains largely inactive orally but blocks opioid effects if the formulation is tampered with, helping to limit abuse.

Side Effects

Oxylaxon may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects

Constipation: reduced gastrointestinal motility.
Nausea: mild to moderate upset stomach.
Drowsiness: increased sedation.
Dizziness: light‑headed feeling.
Dry mouth: reduced salivation.
Sweating: excessive perspiration.

Serious or Rare Side Effects

Respiratory depression: slowed breathing that can be life‑threatening.
Severe hypotension: marked drop in blood pressure.
Opioid use disorder: risk of dependence with prolonged use.
Hepatic impairment: liver function deterioration.
Allergic reaction: rash, itching, swelling, or anaphylaxis.
Seizures: rare convulsive episodes.

Precautions & Warnings

When prescribing Oxylaxon, clinicians should consider several safety measures.

Assess pain severity and prior opioid exposure: ensure appropriate indication.
Evaluate respiratory function: monitor for depression, especially after dose changes.
Review hepatic and renal function: adjust use in impairment.
Avoid concurrent CNS depressants: limit additive sedation risk.
Educate patients on proper use and disposal: reduce accidental ingestion.
Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Oxylaxon can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Benzodiazepines: combined use markedly increases respiratory depression risk.
CNS depressants: other sedatives amplify sedation and respiratory effects.
MAO inhibitors: may provoke severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

Antidepressants (SSRIs, SNRIs): may increase serotonin levels, raising serotonin syndrome risk.
Antihistamines: can enhance drowsiness.
Diuretics: may affect blood pressure control.
CYP3A4 inhibitors (e.g., ketoconazole): raise oxy‑c‑d levels, requiring dose adjustment.

Frequently Asked Questions

Oxylaxon is indicated for the management of moderate to severe pain, including postoperative pain, cancer‑related pain, and chronic non‑cancer pain when other analgesics are insufficient. It provides opioid analgesia while incorporating an antagonist to reduce abuse potential.

Oxycodone hydrochloride binds to μ‑opioid receptors in the central nervous system, inhibiting the transmission of pain signals. In Oxylaxon, naloxone is added to block opioid effects if the tablet is tampered with, helping to deter misuse while allowing normal analgesic action when taken as prescribed.

The appropriate dose of Oxylaxon is determined by the prescribing clinician based on the patient’s pain severity, prior opioid use, and overall health status. Dosage regimens are individualized and should follow local prescribing guidelines.

Oxylaxon is generally not recommended during pregnancy or lactation because opioids can affect fetal development and may be excreted in breast milk. Clinicians must weigh potential benefits against risks and consider alternative therapies when possible.

To order Oxylaxon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Oxylaxon combines oxycodone with naloxone, offering comparable analgesic potency to standard oxycodone tablets while providing an added safety feature that reduces the risk of misuse. This differentiates it from single‑agent opioids that lack an abuse‑deterrent component.

Oxylaxon should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, direct sunlight and excessive heat to maintain product stability.

Oxylaxon is taken orally, usually with water. The tablet should be swallowed whole and not crushed, chewed, or dissolved, as altering the formulation can bypass the naloxone component and increase abuse risk.

The most serious risks include respiratory depression, severe hypotension, opioid dependence, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely, especially during dose initiation or escalation.

Oxylaxon is contraindicated in individuals with known hypersensitivity to oxycodone, naloxone, or any excipients, as well as in patients with severe respiratory depression, acute or severe asthma, and those taking monoamine oxidase inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.